Tricyclo Ring System Which Contains The Hetero Ring As One Of The Cyclos Patents (Class 540/522)
  • Patent number: 5688788
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 18, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: 5679671
    Abstract: The present invention relates to an amino acid derivative having an angiotensin I-converting enzyme inhibition activity, a vasopressin antagonism and an atrial natriuretic peptide hydrolase inhibition activity.This amino acid derivative is represented by the following general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom or an acyl group; R.sup.2 represents a hydrogen atom, a lower alkyl group, a cycloalkyl group, an ary group which may have a substituent, a heteroaryl group which may have a substituent, an arylalkyl group which may have a substituent or a heteroarylalkyl group which may have a substituent;m and n represent each independently an integer of 0, 1 or 2 andJ represents a cyclic group having an angiotensin I-converting enzyme inhibition activity.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: October 21, 1997
    Assignee: Eisai Co., Ltd.
    Inventors: Hitoshi Oinuma, Shinji Suda, Naoki Yoneda, Makoto Kotake, Kenji Hayashi, Kazutoshi Miyake, Nobuyuki Mori, Mamoru Saito, Toshiyuki Matsuoka, Masayuki Namiki, Takeshi Sudo, Shigeru Souda
  • Patent number: 5674866
    Abstract: The present invention is concerned with novel imidazoazepines of formula ##STR1## the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein each of the dotted lines independently represents an optional bond; --A--B-- is a radical of formula --X--CH.dbd.CH-- (a-1); --CH.dbd.CH--X-- (a-2); or --CH.dbd.CH-- CH.dbd.CH-- (a-3); X represents O, S or NR.sup.1 ; R.sup.1 represents hydrogen or C.sub.1-6 alkyl; -----Y is a radical of formula .dbd.O (b-1); --OH (b-2); or .dbd.N--OH (b-3); and L represents hydrogen, C.sub.1-4 alkylcarbonyl, C.sub.1-4 alkyloxycarbonyl, phenylcarbonyl, C.sub.1-6 alkyl or C.sub.1-6 alkyl substituted with C.sub.1-4 alkyloxycarbonyl, hydroxycarbonyl, aryl, aryloxy or a radical of formula ##STR2## --D--Z-- is --S--CH.dbd.CH--, --S--CH.sub.2 --CH.sub.2 --, --S--CH.sub.2 --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 --; and aryl is phenyl or phenyl substituted with halo, hydroxy or C.sub.1-4 alkyloxy.
    Type: Grant
    Filed: December 13, 1995
    Date of Patent: October 7, 1997
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Frans Eduard Janssens, Joseph Elisabeth Leenaerts
  • Patent number: 5668129
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: March 27, 1996
    Date of Patent: September 16, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: 5663166
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: September 2, 1997
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
  • Patent number: 5644055
    Abstract: Disclosed are the compounds of formula I ##STR1## wherein X represents oxo, one hydroxy or lower alkoxy and one hydrogen, or two hydrogens;R.sub.a and R.sub.b independently represent hydrogen, hydroxy, lower alkoxy, nitro, amino or halogen; or R.sub.a and R.sub.b on adjacent carbons taken together represent lower alkylenedioxy;R.sub.c represents hydrogen, lower alkyl or aryl-lower alkyl;R represents hydrogen or acyl;R.sub.1 represents hydrogen, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, biaryl, biaryl-lower alkyl or trifluoromethyl;R.sub.2 represents hydrogen or lower alkyl; or R.sub.1 and R.sub.2 together with the carbon to which they are attached represent cycloalkylene or benzo-fused cycloalkylene;m represents one or two;n represents zero or one;COOR.sub.
    Type: Grant
    Filed: December 20, 1995
    Date of Patent: July 1, 1997
    Assignee: Ciba-Geigy Corporation
    Inventor: Stephane De Lombaert
  • Patent number: 5641880
    Abstract: The present invention relates to novel processes for preparing intermediates of the formula I ##STR1## and to novel intermediates thereof which are useful in the preparation of inhibitors of enkephalinase and angiotensin converting enzyme.
    Type: Grant
    Filed: October 24, 1995
    Date of Patent: June 24, 1997
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Gary A. Flynn, Thomas D. Bannister
  • Patent number: 5629309
    Abstract: The present invention relates to certain novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and of ACE.
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: May 13, 1997
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Douglas W. Beight, Alan M. Warshawsky, Shujaath Mehdi, John F. French, John H. Kehne
  • Patent number: 5604221
    Abstract: The present invention relates to certain novel indane-2-mercaptoacetylamide disulfide derivatives of the formula ##STR1## useful as inhibitors of enkephalinase.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: February 18, 1997
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Douglas W. Beight, Alan M. Warshawsky, Shujaath Mehdi, John H. Kehne
  • Patent number: 5567814
    Abstract: The present invention relates to certain novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and of ACE.
    Type: Grant
    Filed: March 2, 1995
    Date of Patent: October 22, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Douglas W. Beight, Alan M. Warshawsky, Shujaath Mehdi, John F. French, John H. Kehne
  • Patent number: 5545736
    Abstract: The invention relates to 6-thiono-dibenz[b,e]azepines, to a process for their preparation and to their use as inhibitors of reverse transcriptase and in particular as antiretroviral agents.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: August 13, 1996
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hanno Wild, Wolfgang Roeben, Arnold Paessens, J org Petersen-von Gehr
  • Patent number: 5532359
    Abstract: Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: July 2, 1996
    Assignees: Genentech, Inc., Board of Regents, The University of Texas System
    Inventors: James C. Marsters, Jr., Michael S. Brown, Craig W. Crowley, Joseph L. Goldstein, Guy L. James, Robert S. McDowell, David Oare, Thomas E. Rawson, Mark Reynolds, Todd C. Somers
  • Patent number: 5527795
    Abstract: The present invention relates to certain novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and of ACE.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: June 18, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Philippe Bey, Alan M. Warshawsky, Douglas W. Beight, Shujaath Mehdi, Eugene L. Giroux, Timothy P. Burkholder, Edward D. Daugs, John F. French
  • Patent number: 5491143
    Abstract: The present invention relates to certain novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and of ACE.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: February 13, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Philippe Bey, Alan M. Warshawsky, Douglas W. Beight, Shujaath Mehdi, Eugene L. Giroux, Timothy P. Burkholder, Edward D. Daugs, John F. French
  • Patent number: 5488048
    Abstract: The present invention relates to novel aminoacetylmercapto derivatives useful as inhibitors of enkephalinase and ACE.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: January 30, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Robert J. Cregge, Thomas L. Fevig, Shyam Sunder, Patrick W. Shum
  • Patent number: 5484783
    Abstract: The present invention relates to the use of certain mercaptoacetylamide and benzazapine derivatives in treating patients suffering from hypertriglyceridemia, atherosclerosis and hypercholesterolemia.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: January 16, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, John F. French, Richard C. Dage
  • Patent number: 5457196
    Abstract: The present invention relates to novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE.
    Type: Grant
    Filed: December 6, 1993
    Date of Patent: October 10, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Alan M. Warshawsky, Gary A. Flynn
  • Patent number: 5455242
    Abstract: The present invention relates to compounds of the formula ##STR1## wherein B.sub.1 and B.sub.2 are each independently hydrogen; hydroxy; --OR.sub.2 wherein R.sub.2 is a C.sub.1 -C.sub.4 alkyl or an Ar--Y group wherein Ar is aryl and Y is a hydrogen or C.sub.1 -C.sub.4 alkyl; or, where B.sub.1 and B.sub.2 are attached to adjacent carbon atoms, B.sub.1 and B.sub.2 can be taken together with said adjacent carbons to form a benzene ring or methylenedioxy;A is a bond, methylene or oxygen, sulfur or NR.sub.4 or NCOR.sub.5 wherein R.sub.4 is hydrogen, a C.sub.1 -C.sub.4 alkyl or an Ar--Y-- group and R.sub.5 is --CF.sub.3, a C.sub.1 -C.sub.10 alkyl or an Ar--Y-- group;R.sub.3 is hydrogen or --CH.sub.2 OC(O)C(CH.sub.3).sub.3 ;R.sub.1 is hydrogen, C.sub.1 -C.sub.4 alkyl or --CH.sub.2 OC(O)--C(CH.sub.3).sub.3 ; andn is an integer 1 to 3,which are useful as inhibitors of enkephalinase and ACE.
    Type: Grant
    Filed: November 2, 1993
    Date of Patent: October 3, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Alan M. Warshawsky, Gary A. Flynn
  • Patent number: 5430145
    Abstract: The present invention relates to certain novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and of ACE.
    Type: Grant
    Filed: November 9, 1993
    Date of Patent: July 4, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Philippe Bey, Alan M. Warshawsky, Douglas W. Beight, Shujaath Mehdi, Eugene L. Giroux, Timothy P. Burkholder, Edward D. Daugs, John F. French
  • Patent number: 5428158
    Abstract: The present invention relates to novel 2-substituted indane-2-mercaptoacetylamide derivatives which are useful as inhibitors of enkephalinase and ACE.
    Type: Grant
    Filed: November 1, 1993
    Date of Patent: June 27, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Alan M. Warshawsky, Gary A. Flynn
  • Patent number: 5424425
    Abstract: The present invention relates to novel aminoacetylmercapto derivatives useful as inhibitors of enkephalinase and ACE.
    Type: Grant
    Filed: September 10, 1993
    Date of Patent: June 13, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Robert J. Cregge, Thomas L. Fevig, Shyam Sunder, Patrick W. Shum
  • Patent number: 5416209
    Abstract: The invention relates to 5,6-dihydro-dibenz[b,e]azepine-6,11-dione-11-oximes, to processes for their preparation and to their use as inhibitors of reverse transcriptase and in particular as antiretroviral agents.
    Type: Grant
    Filed: November 18, 1992
    Date of Patent: May 16, 1995
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hanno Wild, Wolfgang Roeben, Gerd Aichinger, Arnold Paessens, Jorg Peters n-von Gehr
  • Patent number: 5385899
    Abstract: The invention relates to aminoalkyl-substituted 5,6-dihydro-dibenz[b,e]azepine-6,11-dione-11-oximes, to processes for their preparation and to their use as antiretroviral agents.
    Type: Grant
    Filed: November 17, 1992
    Date of Patent: January 31, 1995
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hanno Wild, Wolfgang Roeben, Gerd Aichinger, Arnold Paessens, Jorg Petersen-von Gehr
  • Patent number: 5362727
    Abstract: Compounds of the formula ##STR1## wherein A is ##STR2## are dual inhibitors of NEP and ACE. Compounds wherein A is ##STR3## are selective as ACE inhibitors. Methods of preparation and intermediates are also disclosed.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: November 8, 1994
    Assignee: Bristol-Myers Squibb
    Inventor: Jeffrey A. Robl
  • Patent number: 5300642
    Abstract: Cognitive defeciencies or neurological dysfunction in mammals are treated with .alpha.,.alpha.-disubstituted aromatic or heteroaromatic compounds. The compounds have the formula: ##STR1## or a salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional aromatic ring or heteroaromatic ring fused to the first ring;one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from(a) 2, 3, or 4-pyridyl,(b) 2, 4, or 5-pyrimidinyl,(c) 2-pyrazinyl,(d) 3, or 4-pyridazinyl,(e) 3, or 4-pyrazolyl,(f) 2, or 3-tetrahydrofuranyl, and(g) 3-thienyl.
    Type: Grant
    Filed: September 30, 1992
    Date of Patent: April 5, 1994
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Richard A. Earl, Melvyn J. Myers, Victor J. Nickolson
  • Patent number: 5296482
    Abstract: The compounds are 3-[ (benzocycloalkyl)alkyl amino alkyl] -1,3,4,5-te trahydro 2H- 3-benzazepin-2 ones useful in cardiovascular field.A compound disclosed is (R,S)-7,8-dimethoxy-3-{3-{N-[(4,5-dimethoxybenzocyclobut-1-yl) methyl]-N-methyl amino}propyl}-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: March 22, 1994
    Assignee: Adir et Compagnie
    Inventors: Jean-Louis Peglion, Joel Vian, Jean-Paul Vilaine, Nicole Villeneuve, Philip Janiak, Jean-Pierre Bidouard
  • Patent number: 5238936
    Abstract: The compounds are trisubstituted triazines and pyrimidines useful for the suppressing the resistance of tumour cells to anti-cancer agents and for suppressing the resistance of parasites to anti-parasitic agents.A compound disclosed is 2,4-diallylamino-6-{4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl) methylamino]piperidin-1-yl}-1,3,5-triazine.
    Type: Grant
    Filed: March 6, 1992
    Date of Patent: August 24, 1993
    Assignee: Adir et Compagnie
    Inventors: Gilbert Regnier, Alain Dhainaut, Ghanem Atassi, Alain Pierre, Stephane Leonce
  • Patent number: 5208230
    Abstract: The present invention relates to compounds of the formula ##STR1## wherein A is methylene, oxygen, sulfur or N-B wherein B is R.sub.1 or COR.sub.2 wherein R.sub.1 is hydrogen, a C.sub.1 -C.sub.4 alkyl or an Ar--Z-- group wherein Ar is aryl and Z is a C.sub.0 -C.sub.4 alkyl and R.sub.2 is a --CF.sub.3, a C.sub.1 -C.sub.10 alkyl or an Ar--Z group;R is hydrogen or a C.sub.1 -C.sub.4 alkyl; andX and Y are each independently hydrogen, nitro or amino, with the proviso that when X is nitro or amino, Y must be hydrogen, and when Y is nitro or amino, X must be hydrogen; andpharmaceutically acceptable salts thereof, which are inhibitors of Angiotensin Converting Enzyme.
    Type: Grant
    Filed: June 25, 1992
    Date of Patent: May 4, 1993
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Gary A. Flynn, Douglas W. Beight
  • Patent number: 5095110
    Abstract: This invention relates to a process for preparing an olifinated tricyclic lactam which comprises reacting an amine with alkylnitrite to form a diazoamide compound which is further reacted with strong acid and phosphine, and finally with a strong base and formaldehyde.
    Type: Grant
    Filed: February 9, 1990
    Date of Patent: March 10, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Douglas W. Beight
  • Patent number: 5037821
    Abstract: A method is provided for inhibiting loss of cognitive function, including memory, which may or may not be associated with Alzheimer's disease, in a mammalian species by administering a benzazepine-type or a pyrimidine-type calcium channel blocker such as diltiazem, SQ 31,765, SQ 32,324, SQ 33,351, SQ 33,537 or SQ 32,547 alone or in combination with an ACE inhibitor, such as captopril or SQ 29,852, over a prolonged period of treatment.
    Type: Grant
    Filed: March 27, 1989
    Date of Patent: August 6, 1991
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Zola P. Horovitz
  • Patent number: 4973585
    Abstract: This invention relates to derivatives of fused bicyclic or tricyclic lactams, to the intermediates and processes useful for their preparation and to their pharmacological effect in inhibiting the angiotensin converting enzyme and to their end-use application in the treatment of hypertension.
    Type: Grant
    Filed: May 10, 1989
    Date of Patent: November 27, 1990
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Gary A. Flynn, Douglas W. Beight
  • Patent number: 4970205
    Abstract: Invented are sulfonic acid substituted analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5-.alpha.-reductase, including using these compounds to reduce or maintain prostate size. Also invented are intermediates used in preparing these compounds.
    Type: Grant
    Filed: December 23, 1988
    Date of Patent: November 13, 1990
    Assignee: SmithKline Beecham Corporation
    Inventors: Dennis A. Holt, Mark A. Levy, Brian W. Metcalf
  • Patent number: 4871735
    Abstract: The present invention relates to new naphthyl derivatives of general formula ##STR1## wherein N represents the number 1 or 2,A represents a --CH.sub.2 --, --CO--, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, ##STR2## while the atom marked with an x is linked to the phenyl nucleus, E represents a straight chained alkylene group optionally substituted by an alkyl group,G represents a straight chained alkylene group optionally substituted by an alkyl group,L represents a bond or an oxygen atom, if G represents a straight chained alkylene group with 2 to 5 carbon atoms optionally substituted by an alkyl group,R.sub.1 and R.sub.2, which may be identical or different, represent alkyl or alkoxy groups or R.sub.1 and R.sub.2 together represent an alkylenedioxy group,R.sub.3 represents a hydrogen atom, or an alkyl or an allyl group,R.sub.4, R.sub.5 and R.sub.
    Type: Grant
    Filed: September 11, 1987
    Date of Patent: October 3, 1989
    Assignee: Dr. Karl Thomae GmbH
    Inventors: Joachim Heider, Manfred Psiorz, Andreas Bomhard, Norbert Hauel, Berthold Narr, Klaus Noll, Christian Lillie, Walter Kobinger, Jurgen Dammgen
  • Patent number: 4824832
    Abstract: This invention relates to conformationally rigid sulfur containing tricyclic lactams, to the intermediates and processes useful for their preparation, and to their pharmacological effects in inhibiting angiotensin converting enzyme, in treating reperfusion injury and in treating heart-failure.
    Type: Grant
    Filed: December 30, 1987
    Date of Patent: April 25, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Douglas W. Beight
  • Patent number: 4678499
    Abstract: Benzenesulfonamide compounds such as N-[(4,6-dimethoxy-1,3,5-triazin-2-yl)aminocarbonyl]-1,4-dihydro-3-methyl-4 -oxo-1-phenyl-indeno[1,2-C]-pyrazole-5-sulfonamide and N-[(4-methoxy-6-methyl-pyrimidin-2-yl)aminocarbonyl]-1,4-dihydro-3-methyl- 4-oxo-1-phenyl-indeno[1,2-C]pyrazole-5-sulfonamide, agricultural compositions containing them, and their herbicidal utility are disclosed.
    Type: Grant
    Filed: January 30, 1986
    Date of Patent: July 7, 1987
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Robert J. Pasteris, Ramaurthi Muthukrishnan
  • Patent number: 4668674
    Abstract: There are described (+)-6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)-acetyl]-11H-dibenzo [b,e][1,4]diazepin-11-one, the isolation thereof from a mixture of enantiomers and its use as a pharmaceutical material.The compound is characterized by a powerful activity against ulcers of the gastro-intestinal tract.
    Type: Grant
    Filed: August 19, 1986
    Date of Patent: May 26, 1987
    Assignee: Dr. Karl Thomae GmbH
    Inventors: G/u/ nter Trummlitz, Wolfhard Engel, Wolfgang Eberlein, Gerhard Mihm, Antonio Giachetti